Teva Pharmaceutical Industries Ltd. announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ.Richard Francis. Dr. Ananth joins Teva with over 34 years of experience leading global API businesses in external sales, internal operations and in contract development and manufacturing operations.

He will lead Teva api through its transformation to a standalone business, which plays a critical part in Teva's Pivot to Growth strategy announced in May 2023. Having led the former Teva api and Biologics Operations organization at Teva from 2014 to 2018, Dr. Ananth has a deep understanding of Teva's API business. Prior to joining Teva, Dr. Ananth previously served as Chief Executive Officer of a portfolio company of a global leading private equity firm, and a leading Contract Development and Manufacturing Organization (CDMO) for large scale production of Active Ingredients (Agro), electronic chemicals, specialty chemicals and intermediates for agro, pharma, dyes & pigments.

Prior to this, he served as Chief Executive Officer of Strides Pharma Science Limited, a global generic pharmaceutical company, and as Chief Operating Officer at Cipla Limited. Earlier in his career, Ananth held various leadership positions leading operations, business development and P&L in the global pharmaceutical industry including at Piramal and Dr Reddy's Laboratories Limited.